Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
5.39
-0.03 (-0.55%)
At close: Mar 4, 2026, 4:00 PM EST
5.45
+0.06 (1.11%)
After-hours: Mar 4, 2026, 7:55 PM EST
Atara Biotherapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Atara Biotherapeutics stock has a target of 6.00, which predicts an increase of 11.32% from the current stock price of 5.39.
Analyst Consensus: Hold
* Price targets were last updated on Jan 13, 2026.
Analyst Ratings
According to 1 stock analyst, the rating for Atara Biotherapeutics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 0 | 0 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 1 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 3 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $25 → $6 | Strong Buy → Hold | Downgrades | $25 → $6 | +11.32% | Jan 13, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $17 → $25 | Strong Buy | Maintains | $17 → $25 | +363.82% | Dec 19, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +215.40% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 22, 2025 |
Financial Forecast
Revenue This Year
123.26M
from 128.94M
Decreased by -4.41%
Revenue Next Year
49.66M
from 123.26M
Decreased by -59.71%
EPS This Year
2.14
from -11.41
EPS Next Year
0.08
from 2.14
Decreased by -96.42%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 130.2M | 76.7M | ||||
| Avg | 123.3M | 49.7M | ||||
| Low | 116.8M | 7.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.0% | -37.8% | ||||
| Avg | -4.4% | -59.7% | ||||
| Low | -9.4% | -94.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.59 | 0.91 | ||||
| Avg | 2.14 | 0.08 | ||||
| Low | 1.69 | -0.71 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | -57.3% | ||||
| Avg | - | -96.4% | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.